Overall, when combining the different subtypes of breast cancer, high levels of ECT2-Ex5 inclusion (ECT2 Ex5+ / ECT2 Ex5- ratio) were associated with shorter metastasis-free survival in patients that were treated with chemotherapy, but not in patients that were not treated with chemotherapy (Supplementary Figure S8A). Here, ECT2 is linked to breast carcinoma.